Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

Fitzgerald, Timothy L.; Melsheimer, Richard; Lafeuille, Marie-Hélène; Lefèbvre, Patrick; Morrison, Laura; Woodruff, Kimberly; Lin, Iris; Émond, Bruno

doi:10.2147/btt.s285610

Cited by 9 publications

(6 citation statements)

References 35 publications

(62 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, switching and discontinuation rates for biologic originators by disease area were not captured. However, interestingly, a recent study conducted by Fitzgerald et al indicated that patients switching from originator to biosimilar infliximab were two to three times more likely to switch to another originator biologic compared to those remaining on originator infliximab [ 75 ]. While results are variable between studies, these findings validate that, at the very least, there is the potential that a patient who undergoes NMS may subsequently undergo dose escalation, or be switched to an alternative treatment or back to the reference biologic, where multiple switches may be associated with greater total healthcare costs [ 32 ].…”

Section: Discussionmentioning

confidence: 99%

The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review

Hillhouse¹,

Mathurin

Parison

et al. 2021

Adv Ther

View full text Add to dashboard Cite

Introduction To save costs to the healthcare system, forced non-medical switch (NMS) policies that cut drug coverage for originator biologics and fund only less expensive biosimilars are being implemented. However, costs related to the impact of NMS on healthcare resource utilization (HCRU) must also be considered. This study aims to summarize the evidence on the economic impact of an originator-to-biosimilar NMS. Methods A systematic literature review (SLR) was conducted. Publications reporting on HCRU or costs associated with originator-to-biosimilar NMS in the real-world setting were searched in MEDLINE and EMBASE from January 2008 to February 2020. In addition to hand searching the reference lists of relevant publications and SLRs, key conference websites, PubMed, and various government sites were also searched for the 2 years preceding the search (2018–2020). Results A total of 1845 citations were identified, of which 49 were retained for data extraction. Most studies reporting on the HCRU associated with NMS reported on post-NMS HCRU alone without a comparison pre-NMS. However, four studies described a difference in HCRU (i.e., investigations pre- vs post-switch or between non-switchers vs switchers), all of which reported a relative increase in HCRU, including laboratory testing, imaging, medical visits, and hospitalizations, amongst patients who underwent an originator-to-biosimilar NMS. Most studies reporting on the costs associated with NMS reported significant savings following NMS on the basis of drug costs alone. However, four studies specifically reporting on the difference of costs following originator-to-biosimilar NMS all demonstrated an increase in HCRU-related costs associated with NMS (increase in HCRU-related costs of 4–37% or 148–2234 2020 Canadian dollars). Conclusion Amongst the studies that reported on the difference in HCRU pre- vs post-switch or between non-switchers and switchers, all showed an increase in HCRU and related costs associated with NMS, suggesting that the expected overall savings due to less costly drug prices may be reduced as a result of an increase in HCRU and its associated costs post-switch. Nevertheless, more real-world studies that include NMS-related healthcare costs in addition to drug costs are needed. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-021-01951-z.

show abstract

Section: Discussionmentioning

confidence: 99%

The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review

Hillhouse¹,

Mathurin

Parison

et al. 2021

Adv Ther

View full text Add to dashboard Cite

show abstract

“…Darüber hinaus zeigte sich, dass die Patienten, die vom Referenzarzneimittel auf das Biosimilar wechselten, 1,25-fach häufiger ihre Therapie unterbrachen als die Patienten, die beim Referenzarzneimittel blieben. Gründe für diese Wechsel konnte die Studie allerdings nicht nennen [ 15 ].…”

Section: Austauschbarkeit Von Biosimilarsunclassified

Einsatz von Biosimilars in der Behandlung der rheumatoiden Arthritis

Morf

Witte

2021

Z Rheumatol

View full text Add to dashboard Cite

ZusammenfassungIn der Therapie der rheumatoiden Arthritis sind seit ca. 20 Jahren Biologika ein fester Bestandteil. Da Arzneimittelpatente in der Regel nach 10 Jahren auslaufen, wurden in den letzten Jahren Biosimilars auf den Markt gebracht. In vielen Studien konnte gezeigt werden, dass sie bei vergleichbarer Sicherheit und Effektivität eine gleichwertige Alternative zum Referenzarzneimittel darstellen. In manchen Fällen zeigten sich sogar geringere Raten an unerwünschten Arzneimittelwirkungen im Vergleich zu den Referenzarzneimitteln. Weiterhin können durch Biosimilars erhebliche Kosten eingespart werden, die sich allein in Deutschland auf einen jährlichen dreistelligen Millionenbetrag belaufen. Dabei lassen sich große regionale Unterschiede bei der Verschreibungshäufigkeit von Biosimilars in Deutschland ausmachen, die sich auch im Einsparungspotenzial widerspiegeln. Eine Umstellung auf ein Biosimilar ist unter Einbezug des Patienten gut möglich und auch erwünscht. In diesem Sinne ist auch die Erstverschreibung eines Biosimilars statt des Referenzarzneimittels zu befürworten.

show abstract

“…Acceleration in cell division is also known to permit a higher error risk during replication. Immune-mediated inflammatory diseases (IMID) collectively describe a group of unrelated disorders that share common inflammatory pathways [11], such as inflammatory bowel disease (IBD), psoriasis (PS), rheumatoid arthritis (RA), spondylarthritis, and uveitis, which belong to the group of age-related non-communicable diseases (NCDs) [11][12][13][14]. Chronic inflammation, oxidative stress, and alterations in telomere length (TL) have been shown to be involved in various age-related NCDs [15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Decrease in RNase HII and Accumulation of lncRNAs/DNA Hybrids: A Causal Implication in Psoriasis?

et al. 2022

View full text Add to dashboard Cite

Functional long non-coding RNAs (lncRNAs) have been in the limelight in aging research because short telomeres are associated with higher levels of TERRA (Telomeric Repeat containing RNA). The genomic instability, which leads to short telomeres, is a mechanism observed in cell aging and in a class of cancer cells. Psoriasis, a skin disease, is a disorder of epidermal keratinocytes, with altered telomerase activity. Research on the fraction of nascent RNAs in hybrid with DNA offers avenues for new strategies. Skin and blood samples from patients were fractionated to obtain the RNA associated with DNA as a R-loop structure. The higher amount of TERRA levels attached with each chromosome end was found with psoriasis patients in blood and skin. In addition to telomeric TERRA, we evidenced accumulation of others non-coding RNA, such as non-telomeric TERRA and centromeric transcripts. Increased levels of non-coding RNAs attached to DNA correlates with a decreased in Ribonuclease HII (RNase-HII) transcript which means that overall unresolved DNA–RNA hybrids can ultimately weaken DNA and cause skin lesions. Since the genome is actively transcribed, cellular RNase-HII is essential for removing RNA from the DNA–RNA hybrid in controls of genome stability and epigenome shaping and can be used as a causal prognostic marker in patients with psoriasis.

show abstract

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

Cited by 9 publications

References 35 publications

The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review

The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review

Einsatz von Biosimilars in der Behandlung der rheumatoiden Arthritis

Decrease in RNase HII and Accumulation of lncRNAs/DNA Hybrids: A Causal Implication in Psoriasis?

Contact Info

Product

Resources

About